Observational Study
Copyright ©The Author(s) 2019.
World J Gastrointest Oncol. May 15, 2019; 11(5): 424-435
Published online May 15, 2019. doi: 10.4251/wjgo.v11.i5.424
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Plasma ADAMTS13:AC and VWF:Ag levels in patients with hepatocellular carcinoma receiving sorafenib treatment. A: ADAMTS13:AC level was significantly higher in patients with hepatocellular carcinoma receiving sorafenib treatment who achieved stable disease (SD), partial response (PR), and complete response (CR) than those who achieved progressive disease (PD) (P < 0.05); B, C: In contrast, VWF:Ag, and the VWF:Ag/ADAMTS13:AC ratio levels were significantly lower in those with SD, PR, and CR than those with PD (P < 0.05, P < 0.05). ADAMTS13: A disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13; ADAMTS13:AC: ADAMTS13 activity; VWF: Von Willebrand factor; VWF:Ag: VWF antigen; VWF:Ag/ADAMTS13:AC ratio: The ratio of VWF:Ag to ADAMTS13:AC; SD: Stable disease; PR: Partial response; CR: Complete response; PD: Progressive disease.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 The relationship between the VWF:Ag/ADAMTS13:AC ratio and tumor-node-metastasis stage. The VWF:Ag/ADAMTS13:AC ratio level was significantly higher in patients with tumor-node-metastasis stage 4 hepatocellular carcinoma (HCC) than those with stage 2 and 3 HCC. ADAMTS13: A disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13; ADAMTS13:AC: ADAMTS13 activity; VWF: Von Willebrand factor; VWF:Ag: VWF antigen; VWF:Ag/ADAMTS13:AC ratio: The ratio of VWF:Ag to ADAMTS13:AC; TNM stage: Tumor-node-metastasis stage.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Diagnostic accuracy of the VWF:Ag/ADAMTS13:AC for sorafenib response. The receiver operating characteristic analysis of the VWF:Ag/ADAMTS13:AC ratio for sorafenib response reveals that a cutoff VWF:Ag/ADAMTS13:AC ratio of 2.609 has a specificity of 84.2% and a sensitivity of 88.2%, with an area under the receiver operating characteristic curve of 0.836. ADAMTS13: A disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13; ADAMTS13:AC: ADAMTS13 activity; VWF: Von Willebrand factor; VWF:Ag: VWF antigen; VWF:Ag/ADAMTS13:AC ratio: The ratio of VWF:Ag to ADAMTS13:AC.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Vascular endothelial growth factor is associated with the VWF:Ag/ADAMTS13:AC ratio and ADAMTS13:AC in patients with hepatocellular carcinoma receiving sorafenib treatment. A: Hepatocellular carcinoma (HCC) patients with a VWF:Ag/ADAMTS13:AC ratio ≥ 2.609 had significantly higher vascular endothelial growth factor (VEGF) levels than those with a VWF:Ag/ADAMTS13:AC ratio < 2.609; B: HCC patients with an ADAMTS13:AC < 78.0 had significantly higher VEGF levels than those with an ADAMTS13:AC ≥ 78.0. ADAMTS13: A disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13; ADAMTS13:AC: ADAMTS13 activity; VWF: Von Willebrand factor; VWF:Ag: VWF antigen; VWF:Ag/ADAMTS13:AC ratio: The ratio of VWF:Ag to ADAMTS13:AC; VEGF: Vascular endothelial growth factor.
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 ADAMTS13 is associated with progression-free survival and overall survival in patients with hepatocellular carcinoma receiving sorafenib treatment. Hepatocellular carcinoma (HCC) patients with an ADAMTS13:AC ≥ 78.0 had significantly longer progression-free survival (A) and overall survival (B) than those with an ADAMTS13:AC < 78.0. Solid and dotted lines indicate HCC patients with an ADAMTS13:AC ≥ 78.0 and an ADAMTS13:AC < 78.0, respectively. ADAMTS13: A disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13; ADAMTS13:AC: ADAMTS13 activity.